Cargando…

The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy

BACKGROUND: Hepatitis C affects over 185 million people around the world. This silent disease is responsible for up to 700,000 deaths per year. Despite the scientific revolution in diagnosis and treatment, hepatitis C control remains a huge challenge due to the cost of effective medications. In resp...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesquita, Fabio, Santos, Melina Erica, Benzaken, Adele, Corrêa, Renato Girade, Cattapan, Elisa, Sereno, Leandro Soares, Naveira, Marcelo Contardo Moscoso
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094040/
https://www.ncbi.nlm.nih.gov/pubmed/27806712
http://dx.doi.org/10.1186/s12889-016-3784-4
_version_ 1782465048747180032
author Mesquita, Fabio
Santos, Melina Erica
Benzaken, Adele
Corrêa, Renato Girade
Cattapan, Elisa
Sereno, Leandro Soares
Naveira, Marcelo Contardo Moscoso
author_facet Mesquita, Fabio
Santos, Melina Erica
Benzaken, Adele
Corrêa, Renato Girade
Cattapan, Elisa
Sereno, Leandro Soares
Naveira, Marcelo Contardo Moscoso
author_sort Mesquita, Fabio
collection PubMed
description BACKGROUND: Hepatitis C affects over 185 million people around the world. This silent disease is responsible for up to 700,000 deaths per year. Despite the scientific revolution in diagnosis and treatment, hepatitis C control remains a huge challenge due to the cost of effective medications. In response to the global outcry of hepatitis epidemic and the need to improve the nation’s public health response, the Ministry of Health of Brazil revolutionized hepatitis C treatment by incorporating highly effective drugs that can be accessed through sustainable and universal means. DISCUSSION: This paper describes the unique process of implementing evidence-informed policy to respond to hepatitis C epidemic through the update of hepatitis C treatment in Brazil based on the estimate of disease prevalence, current international guidelines, and the cost-effectiveness impact in the Brazilian Unified Health System. Through a debate of an experience report, the authors underlie the strategic plan implemented according to the situation analysis that emphasized the need to improve its current response over a relatively short-term period. The comprehensive response is detailed comprising three main objectives: improve treatment outcomes by evaluating and incorporating new and effective medications at a sustainable price; elaborate on clinical guidelines to treat hepatitis C patients; and develop awareness and diagnosis campaigns targeted at the population of interest. In this scenario, Brazil was able to obtain an unprecedented discount for a high-medium income country; provided treatment to more than 7000 individuals in the last 2 months of 2015; and expects to treat 38,000 new patients in 2016. SUMMARY: The remarkable process applied in Brazil was developed according to epidemiological data and scientific evidence, and it was motivated by the engagement of the country in the Sustainable Development Goals, which may inspire other developing countries to identify ways to achieve these goals by 2030.
format Online
Article
Text
id pubmed-5094040
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50940402016-11-07 The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy Mesquita, Fabio Santos, Melina Erica Benzaken, Adele Corrêa, Renato Girade Cattapan, Elisa Sereno, Leandro Soares Naveira, Marcelo Contardo Moscoso BMC Public Health Debate BACKGROUND: Hepatitis C affects over 185 million people around the world. This silent disease is responsible for up to 700,000 deaths per year. Despite the scientific revolution in diagnosis and treatment, hepatitis C control remains a huge challenge due to the cost of effective medications. In response to the global outcry of hepatitis epidemic and the need to improve the nation’s public health response, the Ministry of Health of Brazil revolutionized hepatitis C treatment by incorporating highly effective drugs that can be accessed through sustainable and universal means. DISCUSSION: This paper describes the unique process of implementing evidence-informed policy to respond to hepatitis C epidemic through the update of hepatitis C treatment in Brazil based on the estimate of disease prevalence, current international guidelines, and the cost-effectiveness impact in the Brazilian Unified Health System. Through a debate of an experience report, the authors underlie the strategic plan implemented according to the situation analysis that emphasized the need to improve its current response over a relatively short-term period. The comprehensive response is detailed comprising three main objectives: improve treatment outcomes by evaluating and incorporating new and effective medications at a sustainable price; elaborate on clinical guidelines to treat hepatitis C patients; and develop awareness and diagnosis campaigns targeted at the population of interest. In this scenario, Brazil was able to obtain an unprecedented discount for a high-medium income country; provided treatment to more than 7000 individuals in the last 2 months of 2015; and expects to treat 38,000 new patients in 2016. SUMMARY: The remarkable process applied in Brazil was developed according to epidemiological data and scientific evidence, and it was motivated by the engagement of the country in the Sustainable Development Goals, which may inspire other developing countries to identify ways to achieve these goals by 2030. BioMed Central 2016-11-02 /pmc/articles/PMC5094040/ /pubmed/27806712 http://dx.doi.org/10.1186/s12889-016-3784-4 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Debate
Mesquita, Fabio
Santos, Melina Erica
Benzaken, Adele
Corrêa, Renato Girade
Cattapan, Elisa
Sereno, Leandro Soares
Naveira, Marcelo Contardo Moscoso
The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy
title The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy
title_full The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy
title_fullStr The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy
title_full_unstemmed The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy
title_short The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy
title_sort brazilian comprehensive response to hepatitis c: from strategic thinking to access to interferon-free therapy
topic Debate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094040/
https://www.ncbi.nlm.nih.gov/pubmed/27806712
http://dx.doi.org/10.1186/s12889-016-3784-4
work_keys_str_mv AT mesquitafabio thebraziliancomprehensiveresponsetohepatitiscfromstrategicthinkingtoaccesstointerferonfreetherapy
AT santosmelinaerica thebraziliancomprehensiveresponsetohepatitiscfromstrategicthinkingtoaccesstointerferonfreetherapy
AT benzakenadele thebraziliancomprehensiveresponsetohepatitiscfromstrategicthinkingtoaccesstointerferonfreetherapy
AT correarenatogirade thebraziliancomprehensiveresponsetohepatitiscfromstrategicthinkingtoaccesstointerferonfreetherapy
AT cattapanelisa thebraziliancomprehensiveresponsetohepatitiscfromstrategicthinkingtoaccesstointerferonfreetherapy
AT serenoleandrosoares thebraziliancomprehensiveresponsetohepatitiscfromstrategicthinkingtoaccesstointerferonfreetherapy
AT naveiramarcelocontardomoscoso thebraziliancomprehensiveresponsetohepatitiscfromstrategicthinkingtoaccesstointerferonfreetherapy
AT mesquitafabio braziliancomprehensiveresponsetohepatitiscfromstrategicthinkingtoaccesstointerferonfreetherapy
AT santosmelinaerica braziliancomprehensiveresponsetohepatitiscfromstrategicthinkingtoaccesstointerferonfreetherapy
AT benzakenadele braziliancomprehensiveresponsetohepatitiscfromstrategicthinkingtoaccesstointerferonfreetherapy
AT correarenatogirade braziliancomprehensiveresponsetohepatitiscfromstrategicthinkingtoaccesstointerferonfreetherapy
AT cattapanelisa braziliancomprehensiveresponsetohepatitiscfromstrategicthinkingtoaccesstointerferonfreetherapy
AT serenoleandrosoares braziliancomprehensiveresponsetohepatitiscfromstrategicthinkingtoaccesstointerferonfreetherapy
AT naveiramarcelocontardomoscoso braziliancomprehensiveresponsetohepatitiscfromstrategicthinkingtoaccesstointerferonfreetherapy